Edwards Lifesciences has initiated layoffs across the device developer’s global footprint after completing the $4.2 billion sale of its Critical Care business.
About 3% of the company’s workforce will be affected, Edwards CEO Bernard Zovighian said in an announcement viewed by MassDevice.
Affected employees were notified today, he said, and some may temporarily stay on to help with the Critical Care business transition, while others may find other jobs internally.
https://www.massdevice.com/edwards-lifesciences-layoffs-global-stock-buyback/